Huntington's Disease: Can Mice Lead the Way to Treatment?

Neuron

Volumn 69, Issue 3, 2011, Pages 423-435

  Crook, Zachary R ^a   Housman, David ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; CANNABIDIOL; CARNITINE; CREATINE; FLUOXETINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; HUNTINGTIN; ICOSAPENTAENOIC ACID ETHYL ESTER; KAINIC ACID; METABOTROPIC RECEPTOR ANTAGONIST; MINOCYCLINE; MUTANT PROTEIN; NEUROPILIN; POLYGLUTAMINE; QUINOLINIC ACID; REMACEMIDE; RILUZOLE; SMALL INTERFERING RNA; TETRABENAZINE; UBIDECARENONE; VIRUS VECTOR;

AMINO TERMINAL SEQUENCE; AMNESIA; BRAIN DAMAGE; CAG REPEAT; CELL SURVIVAL; CLINICAL RESEARCH; COGNITIVE DEFECT; DISEASE SEVERITY; DISEASE SIMULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENERGY BALANCE; EXCITOTOXICITY; EXON; EXPERIMENTAL MOUSE; GENE INSERTION; GENE SILENCING; GENE TARGETING; GENETIC PREDISPOSITION; HUMAN; HUNTINGTON CHOREA; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MITOCHONDRIAL ENERGY TRANSFER; MOLECULAR PATHOLOGY; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ROTAROD TEST; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; VISUAL FIELD DEFECT;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENE KNOCK-IN TECHNIQUES; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC;

EID: 79551655290     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2010.12.035     Document Type: Review

References (146)

1. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 2001, 8:479-491.
2. Bates G., Harper P., Jones L. Huntington's Disease 2002, Oxford University Press, New York. Third Edition.
3. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321:168-171.
4. Beal M.F., Ferrante R.J., Swartz K.J., Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 1991, 11:1649-1659.
5. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13:4181-4192.
6. Benn C.L., Butler R., Mariner L., Nixon J., Moffitt H., Mielcarek M., Woodman B., Bates G.P. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS ONE 2009, 4:e5747.
7. Bennett E.J., Shaler T.A., Woodman B., Ryu K.-Y., Zaitseva T.S., Becker C.H., Bates G.P., Schulman H., Kopito R.R. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708.
8. Björkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R.V., Benn C.L., Soulet D., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
9. Boudreau R.L., McBride J.L., Martins I., Shen S., Xing Y., Carter B.J., Davidson B.L. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther. 2009, 17:1053-1063.
10. Boutell J.M., Thomas P., Neal J.W., Weston V.J., Duce J., Harper P.S., Jones A.L. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet. 1999, 8:1647-1655.
11. Bradford J., Shin J.-Y., Roberts M., Wang C.-E., Li X.-J., Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci. USA 2009, 106:22480-22485.
12. Brustovetsky N., LaFrance R., Purl K.J., Brustovetsky T., Keene C.D., Low W.C., Dubinsky J.M. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease. J. Neurochem. 2005, 93:1361-1370.
13. Cannella M., Gellera C., Maglione V., Giallonardo P., Cislaghi G., Muglia M., Quattrone A., Pierelli F., Di Donato S., Squitieri F. The gender effect in juvenile Huntington disease patients of Italian origin. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2004, 125B:92-98.
14. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 1999, 19:3248-3257.
15. Chan E.Y.W., Luthi-Carter R., Strand A., Solano S.M., Hanson S.A., DeJohn M.M., Kooperberg C., Chase K.O., DiFiglia M., Young A.B., et al. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet. 2002, 11:1939-1951.
16. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6:797-801.
17. Como P.G., Rubin A.J., O'Brien C.F., Lawler K., Hickey C., Rubin A.E., Henderson R., McDermott M.P., McDermott M., Steinberg K., Shoulson I. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease. Mov. Disord. 1997, 12:397-401.
18. Consroe P., Laguna J., Allender J., Snider S., Stern L., Sandyk R., Kennedy K., Schram K. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol. Biochem. Behav. 1991, 40:701-708.
19. Coyle J.T., Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976, 263:244-246.
20. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
21. Cummings D.M., Milnerwood A.J., Dallérac G.M., Waights V., Brown J.Y., Vatsavayai S.C., Hirst M.C., Murphy K.P.S.J. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:2856-2868.
22. Cummings D.M., Milnerwood A.J., Dallérac G.M., Vatsavayai S.C., Hirst M.C., Murphy K.P.S.J. Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease. Brain Res. Bull. 2007, 72:103-107.
23. Cybulska-Klosowicz A., Mazarakis N.K., Van Dellen A., Blakemore C., Hannan A.J., Kossut M. Impaired learning-dependent cortical plasticity in Huntington's disease transgenic mice. Neurobiol. Dis. 2004, 17:427-434.
24. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
25. Dorner J.L., Miller B.R., Barton S.J., Brock T.J., Rebec G.V. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease. Behav. Brain Res. 2007, 178:90-97.
26. Dunah A.W., Jeong H., Griffin A., Kim Y.-M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
27. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
28. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., Beal M.F. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 2002, 22:1592-1599.
29. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
30. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: An open-label continuation study. BMC Neurol. 2009, 9:62. Huntington Study Group/TETRA-HD Investigators.
31. Gardian G., Browne S.E., Choi D.-K., Klivenyi P., Gregorio J., Kubilus J.K., Ryu H., Langley B., Ratan R.R., Ferrante R.J., Beal M.F. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280:556-563.
32. Gil J.M., Rego A.C. The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease. Brain Res. Brain Res. Rev. 2009, 59:410-431.
33. Ginés S., Bosch M., Marco S., Gavaldà N., Díaz-Hernández M., Lucas J.J., Canals J.M., Alberch J. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur. J. Neurosci. 2006, 23:649-658.
34. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
35. Goetz C.G., Tanner C.M., Cohen J.A., Thelen J.A., Carroll V.S., Klawans H.L., Fariello R.G. L-acetyl-carnitine in Huntington's disease: Double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov. Disord. 1990, 5:263-265.
36. Gourfinkel-An I., Cancel G., Duyckaerts C., Faucheux B., Hauw J.J., Trottier Y., Brice A., Agid Y., Hirsch E.C. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. Neuroreport 1998, 9:1823-1826.
37. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
38. Graham R.K., Pouladi M.A., Joshi P., Lu G., Deng Y., Wu N.-P., Figueroa B.E., Metzler M., André V.M., Slow E.J., et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J. Neurosci. 2009, 29:2193-2204.
39. Gray M., Shirasaki D.I., Cepeda C., André V.M., Wilburn B., Lu X.-H., Tao J., Yamazaki I., Li S.-H., Sun Y.E., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
40. Grote H.E., Bull N.D., Howard M.L., van Dellen A., Blakemore C., Bartlett P.F., Hannan A.J. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur. J. Neurosci. 2005, 22:2081-2088.
41. Gu X., Greiner E.R., Mishra R., Kodali R., Osmand A., Finkbeiner S., Steffan J.S., Thompson L.M., Wetzel R., Yang X.W. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 2009, 64:828-840.
42. Gu X., Li C., Wei W., Lo V., Gong S., Li S.-H., Iwasato T., Itohara S., Li X.-J., Mody I., et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005, 46:433-444.
43. Hansson O., Petersén A., Leist M., Nicotera P., Castilho R.F., Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. USA 1999, 96:8727-8732.
44. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur. J. Neurosci. 2001, 14:1492-1504.
45. Heng M.Y., Tallaksen-Greene S.J., Detloff P.J., Albin R.L. Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease. J. Neurosci. 2007, 27:8989-8998.
46. Herndon E.S., Hladik C.L., Shang P., Burns D.K., Raisanen J., White C.L. Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains. J. Neuropathol. Exp. Neurol. 2009, 68:250-261.
47. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M., Como P., Zimmerman C., Lin M., Zhang L., et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006, 66:250-252.
48. Hickey M.A., Kosmalska A., Enayati J., Cohen R., Zeitlin S., Levine M.S., Chesselet M.-F. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 2008, 157:280-295.
49. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., Sathasivam K., Ghazi-Noori S., Mahal A., Lowden P.A.S., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 2003, 100:2041-2046.
50. Hodges A., Hughes G., Brooks S., Elliston L., Holmans P., Dunnett S.B., Jones L. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease. Genes Brain Behav. 2008, 7:288-299.
51. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
52. Hoffner G., Djian P. Protein aggregation in Huntington's disease. Biochimie 2002, 84:273-278.
53. Huang C.C., Faber P.W., Persichetti F., Mittal V., Vonsattel J.P., MacDonald M.E., Gusella J.F. Amyloid formation by mutant huntingtin: Threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 1998, 24:217-233.
54. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404. Huntington Study Group.
55. Dosage effects of riluzole in Huntington's disease: A multicenter placebo-controlled study. Neurology 2003, 61:1551-1556. Huntington Study Group.
56. Minocycline safety and tolerability in Huntington disease. Neurology 2004, 63:547-549. Huntington Study Group.
57. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology 2006, 66:366-372. Huntington Study Group.
58. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: The TREND-HD study. Arch. Neurol. 2008, 65:1582-1589. Huntington Study Group TREND-HD Investigators.
59. Ishiguro H., Yamada K., Sawada H., Nishii K., Ichino N., Sawada M., Kurosawa Y., Matsushita N., Kobayashi K., Goto J., et al. Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene. J. Neurosci. Res. 2001, 65:289-297.
60. Jarabek B.R., Yasuda R.P., Wolfe B.B. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 2004, 127:505-516.
61. Jenkins B.G., Andreassen O.A., Dedeoglu A., Leavitt B., Hayden M., Borchelt D., Ross C.A., Ferrante R.J., Beal M.F. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J. Neurochem. 2005, 95:553-562.
62. Kennedy L., Shelbourne P.F. Dramatic mutation instability in HD mouse striatum: Does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?. Hum. Mol. Genet. 2000, 9:2539-2544.
63. Kennedy L., Evans E., Chen C.-M., Craven L., Detloff P.J., Ennis M., Shelbourne P.F. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum. Mol. Genet. 2003, 12:3359-3367.
64. Kieburtz K., Feigin A., McDermott M., Como P., Abwender D., Zimmerman C., Hickey C., Orme C., Claude K., Sotack J., et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov. Disord. 1996, 11:273-277.
65. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 2001, 86:2667-2677.
66. Kuhn A., Goldstein D.R., Hodges A., Strand A.D., Sengstag T., Kooperberg C., Becanovic K., Pouladi M.A., Sathasivam K., Cha J.-H.J., et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 2007, 16:1845-1861.
67. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., et al. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 2001, 21:9112-9123.
68. Leeflang E.P., Tavaré S., Marjoram P., Neal C.O., Srinidhi J., MacFarlane H., MacDonald M.E., Gusella J.F., de Young M., Wexler N.S., Arnheim N. Analysis of germline mutation spectra at the Huntington's disease locus supports a mitotic mutation mechanism. Hum. Mol. Genet. 1999, 8:173-183.
69. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 1999, 58:515-532.
70. Li H., Li S.H., Johnston H., Shelbourne P.F., Li X.J. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat. Genet. 2000, 25:385-389.
71. Li J.Y., Popovic N., Brundin P. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2005, 2:447-464.
72. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 2001, 10:137-144.
73. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 1999, 19:10428-10437.
74. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 2000, 9:1259-1271.
75. Luthi-Carter R., Strand A.D., Hanson S.A., Kooperberg C., Schilling G., La Spada A.R., Merry D.E., Young A.B., Ross C.A., Borchelt D.R., Olson J.M. Polyglutamine and transcription: Gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 2002, 11:1927-1937.
76. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
77. Mangiarini L., Sathasivam K., Mahal A., Mott R., Seller M., Bates G.P. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat. Genet. 1997, 15:197-200.
78. Manley K., Shirley T.L., Flaherty L., Messer A. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat. Genet. 1999, 23:471-473.
79. Matthews R.T., Yang L., Jenkins B.G., Ferrante R.J., Rosen B.R., Kaddurah-Daouk R., Beal M.F. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 1998, 18:156-163.
80. Meade C.A., Deng Y.-P., Fusco F.R., Del Mar N., Hersch S., Goldowitz D., Reiner A. Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice. J. Comp. Neurol. 2002, 449:241-269.
81. Menalled L., Zanjani H., MacKenzie L., Koppel A., Carpenter E., Zeitlin S., Chesselet M.F. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp. Neurol. 2000, 162:328-342.
82. Menalled L.B., Sison J.D., Wu Y., Olivieri M., Li X.-J., Li H., Zeitlin S., Chesselet M.-F. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 2002, 22:8266-8276.
83. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., Chesselet M.-F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 2003, 465:11-26.
84. Menalled L., El-Khodor B.F., Patry M., Suárez-Fariñas M., Orenstein S.J., Zahasky B., Leahy C., Wheeler V., Yang X.W., MacDonald M., et al. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis. 2009, 35:319-336.
85. Mestre T., Ferreira J., Coelho M.M., Rosa M., Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst. Rev. 2009, 3:CD006456. 10.1002/14651858.CD006456.pub2.
86. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., Kennedy R.T., Rebec G.V. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008, 153:329-337.
87. Molero A.E., Gokhan S., Gonzalez S., Feig J.L., Alexandre L.C., Mehler M.F. Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease. Proc. Natl. Acad. Sci. USA 2009, 106:21900-21905.
88. Morton A.J., Lagan M.A., Skepper J.N., Dunnett S.B. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. J. Neurocytol. 2000, 29:679-702.
89. Morton A.J., Glynn D., Leavens W., Zheng Z., Faull R.L.M., Skepper J.N., Wight J.M. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis. 2009, 33:331-341.
90. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci. 2000, 20:5115-5123.
91. Myers R.H., MacDonald M.E., Koroshetz W.J., Duyao M.P., Ambrose C.M., Taylor S.A., Barnes G., Srinidhi J., Lin C.S., Whaley W.L., et al. De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat. Genet. 1993, 5:168-173.
92. Naver B., Stub C., Møller M., Fenger K., Hansen A.K., Hasholt L., Sørensen S.A. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 2003, 122:1049-1057.
93. Nørremølle A., Riess O., Epplen J.T., Fenger K., Hasholt L., Sørensen S.A. Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum. Mol. Genet. 1993, 2:1475-1476.
94. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
95. Oliveira J.M.A., Jekabsons M.B., Chen S., Lin A., Rego A.C., Gonçalves J., Ellerby L.M., Nicholls D.G. Mitochondrial dysfunction in Huntington's disease: The bioenergetics of isolated and in situ mitochondria from transgenic mice. J. Neurochem. 2007, 101:241-249.
96. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., Robbins T.W., Sahakian B.J., Dunnett S.B., Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: A PET study. Brain 2003, 126:1127-1135.
97. Petersén A., Chase K., Puschban Z., DiFiglia M., Brundin P., Aronin N. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Exp. Neurol. 2002, 175:297-300.
98. Reiner A., Del Mar N., Deng Y.-P., Meade C.A., Sun Z., Goldowitz D. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice. J. Comp. Neurol. 2007, 505:603-629.
99. Sadri-Vakili G., Menon A.S., Farrell L.A., Keller-McGandy C.E., Cantuti-Castelvetri I., Standaert D.G., Augood S.J., Yohrling G.J., Cha J.-H.J. Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse. Eur. J. Neurosci. 2006, 23:3171-3175.
100. Sagredo O., Ramos J.A., Decio A., Mechoulam R., Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur. J. Neurosci. 2007, 26:843-851.
101. Sawiak S.J., Wood N.I., Williams G.B., Morton A.J., Carpenter T.A. Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2009, 33:12-19.
102. Schiefer J., Landwehrmeyer G.B., Lüesse H.-G., Sprünken A., Puls C., Milkereit A., Milkereit E., Kosinski C.M. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord. 2002, 17:748-757.
103. Schiefer J., Sprünken A., Puls C., Lüesse H.-G., Milkereit A., Milkereit E., Johann V., Kosinski C.M. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res. 2004, 1019:246-254.
104. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999, 8:397-407.
105. Schilling G., Savonenko A.V., Coonfield M.L., Morton J.L., Vorovich E., Gale A., Neslon C., Chan N., Eaton M., Fromholt D., et al. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp. Neurol. 2004, 187:137-149.
106. Seo H., Kim W., Isacson O. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Hum. Mol. Genet. 2008, 17:3144-3153.
107. Sharp A.H., Ross C.A. Neurobiology of Huntington's disease. Neurobiol. Dis. 1996, 3:3-15.
108. Shelbourne P.F., Killeen N., Hevner R.F., Johnston H.M., Tecott L., Lewandoski M., Ennis M., Ramirez L., Li Z., Iannicola C., et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet. 1999, 8:763-774.
109. Simmons D.A., Rex C.S., Palmer L., Pandyarajan V., Fedulov V., Gall C.M., Lynch G. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc. Natl. Acad. Sci. USA 2009, 106:4906-4911.
110. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.-Z., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2003, 12:1555-1567.
111. Slow E.J., Graham R.K., Osmand A.P., Devon R.S., Lu G., Deng Y., Pearson J., Vaid K., Bissada N., Wetzel R., et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. USA 2005, 102:11402-11407.
112. Southwell A.L., Ko J., Patterson P.H. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci. 2009, 29:13589-13602.
113. Spampanato J., Gu X., Yang X.W., Mody I. Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. Neuroscience 2008, 157:606-620.
114. Spires T.L., Grote H.E., Garry S., Cordery P.M., Van Dellen A., Blakemore C., Hannan A.J. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur. J. Neurosci. 2004, 19:2799-2807.
115. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., Ryu H., Hersch S.M., Ferrante R.J. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 2005, 490:354-370.
116. Stack E.C., Dedeoglu A., Smith K.M., Cormier K., Kubilus J.K., Bogdanov M., Matson W.R., Yang L., Jenkins B.G., Luthi-Carter R., et al. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J. Neurosci. 2007, 27:12908-12915.
117. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., Gohler H., Wanker E.E., Bates G.P., Housman D.E., Thompson L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 2000, 97:6763-6768.
118. Strand A.D., Baquet Z.C., Aragaki A.K., Holmans P., Yang L., Cleren C., Beal M.F., Jones L., Kooperberg C., Olson J.M., Jones K.R. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J. Neurosci. 2007, 27:11758-11768.
119. Tallaksen-Greene S.J., Crouse A.B., Hunter J.M., Detloff P.J., Albin R.L. Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice. Neuroscience 2005, 131:843-852.
120. Tang T.-S., Chen X., Liu J., Bezprozvanny I. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J. Neurosci. 2007, 27:7899-7910.
121. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
122. Thomas E.A., Coppola G., Desplats P.A., Tang B., Soragni E., Burnett R., Gao F., Fitzgerald K.M., Borok J.F., Herman D., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. USA 2008, 105:15564-15569.
123. Trueman R.C., Brooks S.P., Jones L., Dunnett S.B. Rule learning, visuospatial function and motor performance in the Hdh(Q92) knock-in mouse model of Huntington's disease. Behav. Brain Res. 2009, 203:215-222.
124. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 2000, 97:8093-8097.
125. Usdin M.T., Shelbourne P.F., Myers R.M., Madison D.V. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum. Mol. Genet. 1999, 8:839-846.
126. Vamos E., Voros K., Vecsei L., Klivenyi P. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. Biomed. Pharmacother. 2010, 64:282-286.
127. van Dellen A., Blakemore C., Deacon R., York D., Hannan A.J. Delaying the onset of Huntington's in mice. Nature 2000, 404:721-722.
128. Van Raamsdonk J.M., Murphy Z., Slow E.J., Leavitt B.R., Hayden M.R. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2005, 14:3823-3835.
129. Van Raamsdonk J.M., Pearson J., Rogers D.A., Lu G., Barakauskas V.E., Barr A.M., Honer W.G., Hayden M.R., Leavitt B.R. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp. Neurol. 2005, 196:266-272.
130. Van Raamsdonk J.M., Pearson J., Slow E.J., Hossain S.M., Leavitt B.R., Hayden M.R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci. 2005, 25:4169-4180.
131. Vatsavayai S.C., Dallérac G.M., Milnerwood A.J., Cummings D.M., Rezaie P., Murphy K.P.S.J., Hirst M.C. Progressive CAG expansion in the brain of a novel R6/1-89Q mouse model of Huntington's disease with delayed phenotypic onset. Brain Res. Bull. 2007, 72:98-102.
132. Walker A.G., Miller B.R., Fritsch J.N., Barton S.J., Rebec G.V. Altered information processing in the prefrontal cortex of Huntington's disease mouse models. J. Neurosci. 2008, 28:8973-8982.
133. Wang H., Chen X., Li Y., Tang T.-S., Bezprozvanny I. Tetrabenazine is neuroprotective in Huntington's disease mice. Mol. Neurodegener. 2010, 5:18.
134. Weeks R.A., Piccini P., Harding A.E., Brooks D.J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 1996, 40:49-54.
135. Wheeler V.C., Auerbach W., White J.K., Srinidhi J., Auerbach A., Ryan A., Duyao M.P., Vrbanac V., Weaver M., Gusella J.F., et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 1999, 8:115-122.
136. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 2000, 9:503-513.
137. Wheeler V.C., Gutekunst C.-A., Vrbanac V., Lebel L.-A., Schilling G., Hersch S., Friedlander R.M., Gusella J.F., Vonsattel J.-P., Borchelt D.R., MacDonald M.E. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet. 2002, 11:633-640.
138. Wheeler V.C., Lebel L.-A., Vrbanac V., Teed A., te Riele H., MacDonald M.E. Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. Hum. Mol. Genet. 2003, 12:273-281.
139. Wheeler V.C., Persichetti F., McNeil S.M., Mysore J.S., Mysore S.S., MacDonald M.E., Myers R.H., Gusella J.F., Wexler N.S. Factors associated with HD CAG repeat instability in Huntington disease. J. Med. Genet. 2007, 44:695-701. US-Venezuela Collaborative Research Group.
140. Woodman B., Butler R., Landles C., Lupton M.K., Tse J., Hockly E., Moffitt H., Sathasivam K., Bates G.P. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 2007, 72:83-97.
141. Yamada M., Sato T., Tsuji S., Takahashi H. CAG repeat disorder models and human neuropathology: Similarities and differences. Acta Neuropathol. 2008, 115:71-86.
142. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
143. Yu Z.-X., Li S.-H., Evans J., Pillarisetti A., Li H., Li X.-J. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 2003, 23:2193-2202.
144. Zádori D., Geisz A., Vámos E., Vécsei L., Klivényi P. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol. Biochem. Behav. 2009, 94:148-153.
145. Zhang J., Peng Q., Li Q., Jahanshad N., Hou Z., Jiang M., Masuda N., Langbehn D.R., Miller M.I., Mori S., et al. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. Neuroimage 2010, 49:2340-2351.
146. Zucker B., Luthi-Carter R., Kama J.A., Dunah A.W., Stern E.A., Fox J.H., Standaert D.G., Young A.B., Augood S.J. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: Neuronal selectivity and potential neuroprotective role of HAP1. Hum. Mol. Genet. 2005, 14:179-189.